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Comorbid diseases can affect breast cancer prognosis. We conducted a population-based study of Danish women diagnosed with a
first primary breast cancer from 1995 to 2005 (n¼9300), using hospital discharge registry data to quantify comorbidities by Charlson
score. We examined the influence of comorbidities on survival, and quantified their impact on relative mortality rates. The prevalence
of patients with a Charlson score¼‘0’ fell from 86 to 81%, with an increase in those with Charlson score¼‘1–2’ from 13 to 16%,
and score¼‘3þ’ from 1 to 2%. One- and five-year survival for patients with Charlson score¼‘0’ and ‘1–2’ was better for those
diagnosed in 1998–2000 than in 1995–1997. Overall, patients diagnosed in 2001–2004 (mortality ratio (MR)¼0.80, 95%
CI¼0.68–0.95) and 1998–2000 (MR¼0.92, 95% CI¼0.78–1.09) had lower 1-year age-adjusted mortality compared to those
diagnosed in 1995–1997 (reference period). Patients with Charlson scores ‘1–2’ and ‘3þ’ had higher age-adjusted 1-year mortality
than those with a Charlson score¼‘0’ in each time period (2001–2004: MR‘1–2’¼1.76, 95% CI¼1.35–2.30, and MR‘3þ’¼3.78,
95% CI¼2.51–5.68; and 1998–2000: MR‘1–2’¼1.60, 95% CI¼1.36–1.88 and MR‘3þ’¼2.34, 95% CI¼1.65–3.33). Similar findings
were observed for 5-year age-adjusted mortality. Additional analyses, adjusted for stage, indicated that confounding by stage could
not explain these findings. Despite continued improvements in breast cancer survival, we found a trend of poorer survival among
breast cancer patients with severe comorbidities even after adjusting for age and stage. Such poorer survival is an important public
health concern and can be expected to worsen as the population ages.
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Breast cancer accounts for a substantial proportion of the cancer
burden, with over 1000000 new cases diagnosed and over 400000
breast cancer-related deaths worldwide each year (Parkin et al,
2005). Denmark has the highest age-standardised breast cancer
incidence rate, and one of the highest mortality rates in the world
(Globocan, 2006; National Board of Health, 2006).
Over 50% of newly diagnosed breast cancers occur in women
aged 60 years or older. Many of these women have coexistent
diseases (comorbidities) at the time of their breast cancer
diagnosis, which can substantially influence their diagnostic
work-up, treatment options, and survival (West et al, 1996;
Potosky et al, 2002; Harlan et al, 2003a; Louwman et al, 2005). The
presence of comorbidities at diagnosis can have a negative impact
on prognosis and survival (West et al, 1996; Cronin et al, 2005),
and two small studies have indicated that breast cancer patients
with comorbid conditions have lower survival compared to those
without comorbidities (Charlson et al, 1987; West et al, 1996).
The change in population demographics, in terms of population
aging (Coebergh, 1996), will result in an increased proportion of
elderly cancer patients, many of whom present with comorbid
diseases. A study by Louwman et al (2005) indicated that 10%
of patients aged less than 50 years had comorbid conditions
compared to 55% of patients aged over 80 years.
We present a population-based study of the impact of
comorbidity (as measured by the Charlson comorbidity score,
originally validated using 10-year survival in breast cancer
patients) on breast cancer survival and mortality in a Danish
population from 1995 to 2005 (Charlson et al, 1987). We examine




We identified all patients with a diagnosis of breast cancer (ICD-8
code 174.xx and ICD-10 code C50.x) from 1 January 1995 through
31 March 2004, using the hospital discharge registries of four
Danish counties; North Jutland, Aarhus, Viborg, and Ringkjøbing.
In Denmark, all health-related services are registered to individual
patients by use of their civil personal registry number (CPR),
assigned to all Danish citizens since 1968, which denotes gender
and date of birth. This unique CPR number facilitates linkage
between population-based registries (Gaist et al, 1997). The
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yregistries include all non-psychiatric hospital admissions
(since 1977) and outpatient hospital visits (since 1995). Informa-
tion is recorded immediately after discharge and includes
CPR number, dates of admission and discharge, and up to 20
discharge diagnoses (Andersen et al, 1999). Diagnoses are
classified according to the International Classification of Diseases
(ICD), 8th revision until the end of 1993 and the 10th revision
thereafter.
Comorbidities at diagnosis
We included information on comorbidities up to 10 years
before breast cancer diagnosis. Comorbidities were identified
using the hospital discharge registries of each county and were
categorised using the Charlson index. The index comprises 19
conditions, each weighted according to its potential to influence
mortality (Charlson et al, 1987). We used Deyo’s adaptation
of the Charlson comorbidity score, which adapts the Charlson
clinical comorbidity index for research relying on ICD-10
codes (Deyo et al, 1992). Breast cancer diagnoses were not
included when computing the index. We grouped patients
according to a Charlson score of ‘0’, ‘1–2’, or ‘3þ’, groupings
which translate into ‘mild’, ‘moderate’, and ‘severe’ illness
(Charlson et al, 1987).
Stage at diagnosis
Information on stage is not included in the hospital discharge
registries. To obtain information on breast cancer stage at
diagnosis, we used the CPR number to link to the Danish Cancer
Registry. The Danish Cancer Registry is a population-based
nationwide registry with data on incident cases of cancer in
Denmark since 1943, including civil registration number, method
of verification of the cancer, stage, and residence at date of cancer
diagnosis. The registry receives notifications from hospital
departments, institutes of forensic medicine, general practitioners,
and practising specialists The registry is not, however, entirely up
to date. Data are complete through 2002.
Vital status
We linked members of the study cohort via their CPR number to
the Danish Civil Registry to obtain vital status. The Danish Civil
Registry is updated daily and has maintained records on vital
status, date of death, and the residence of all Danish citizens since
1 April 1968. Follow-up was through patient date of death or 31
January 2005, whichever occurred first.
Statistical analyses
We present distribution frequencies (numbers and percentages) of
breast cancer patients in each Charlson score category for each
period of diagnosis. We plotted Kaplan–Meier curves for breast
cancer patients according to the periods of diagnosis – 1995–1997,
1998–2000 and 2001–2004, age, and comorbidity categories. All
time periods were 36 months long, except for the last time period,
which included 39 months. We calculated survival at 1 and 5 years
by product limit methods for each group, except for 5-year
survival for patients diagnosed from 2001 to 2004. We used Cox
proportional hazards regression analysis to compute 1- and 5-year
crude and age-adjusted hazard ratios as a measure of relative
mortality to assess the association of comorbidity with relative
mortality using the Charlson score ‘0’ as the reference category in
each time period. For the patients with available stage information,
we carried out a subanalysis adjusting mortality ratios for both age
and stage.
RESULTS
Table 1 illustrates the number and percentage of patients for each
Charlson comorbidity score by diagnostic period. A total of 9300
breast cancer cases were included, 2819 diagnosed in 1995–1997,
3003 diagnosed in 1998–2000, and 3478 diagnosed from 2001–
2004. The prevalence of patients with Charlson score ‘0’ fell from
86 to 81% over the time period, with corresponding increases in
the prevalence of patients with Charlson scores ‘1–2’ (3% increase)
and ‘3þ’ (1% increase). For all three time periods, median age at
diagnosis did not change for patients with a Charlson score ‘0’ (59
out of 60 years) or a Charlson score ‘1–2’ (72 out of 73 years).
Among patients with a Charlson score ‘3þ’, however, there was a
gradual increase in the median age at diagnosis with each
diagnostic period from age 72 to 76 years in the respective
calendar year categories. The highest number of patients resided
in Aarhus and North-Jutland Counties because of population
demographics. There was a sharp increase in the proportion of
patients with a Charlson score ‘1–2’ in Ringkojbing County from
1995–1997 to 1998–2000 from 8 to 14%, and then to 17% in 2001–
2004. There was an increase in the proportion of breast cancers in
the latest period in all counties.
Figure 1 shows survival curves for breast cancer patients
diagnosed in each period according to Charlson comorbidity score
category. A slightly better survival was noted among patients with
Charlson score ‘0’ diagnosed from 2001 to 2004, and with Charlson
score ‘1–2’ diagnosed from 1998 to 2000 and from 2001 to 2004
(Figure 1A and B). There was no improvement in survival for
patients with Charlson scores ‘3þ’ over the time periods
(Figure 1C).
Table 1 Number and percentage distribution of breast cancer patients
by Charlson comorbidity score diagnosed in three time periods in
Denmark
Charlson score
0 1–2 3+ Total
1995–1997 2423 360 36 2819
86% 13% 1% 100%
Median age in years (1995–1997) 59 73 72
County of residence
North Jutland 758 (84%) 129 (14%) 16 (2%) 903
Aarhus 954 (86%) 138 (13%) 14 (1%) 1106
Viborg 319 (84%) 60 (16%) 3 (1%) 382
Ringkojbing 392 (92%) 33 (8%) 3 (1%) 428
1998–2000 2518 431 54 3003
84% 14% 2% 100%
Median age in years (1998–2000) 60 72 73
County of residence
North Jutland 818 (82%) 158 (16%) 24 (2%) 1000
Aarhus 935 (87%) 131 (12%) 12 (1%) 1078
Viborg 329 (79%) 73 (18%) 13 (3%) 415
Ringkojbing 436 (86%) 69 (14%) 5 (1%) 510
2001–2004 2829 565 84 3478
81% 16% 2% 100%
Median age in years (2001–2004) 59 72 76
County of residence
North Jutland 903 (81%) 184 (16%) 33 (3%) 1120
Aarhus 1069 (82%) 207 (16%) 26 (2%) 1302
Viborg 410 (81%) 82 (16%) 13 (3%) 505
Ringkojbing 447 (81%) 92 (17%) 12 (2%) 551
Total 7770 1356 174 9300
Percentages have been rounded to the nearest decimal place and therefore may not
sum to 100%.
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yTable 2 outlines the cumulative proportion of patients surviving
at 1-year and 5-years as well as the crude and adjusted relative
mortality rates comparing patients with positive Charlson
comorbidity scores to those with Charlson score ‘0’. One-year
survival of patients with Charlson score ‘0’ was similar for all three
diagnostic periods. Five-year survival was slightly better in patients
diagnosed in 1998–2000 (70%, 95% CI¼68–72%) compared to
those diagnosed in 1995–1997 (68%, 95% CI¼66–69%). One-year
survival was also better among patients with Charlson score ‘1–2’
diagnosed in 2001–2004 compared to those diagnosed during the
earlier periods (85 compared to 81% (1998–2000) and 79% (1995–
1997)). Among patients with Charlson score ‘3þ’, 1-year survival
was lowest in those diagnosed from 2001–2004 (67%, 95%
CI¼55–76%), compared to those diagnosed in 1998–2000 (80%,
95% CI¼66–88%) and in 1995–1997 (72%, 95% CI¼55–84%).
Patients with non-zero comorbidity scores had poorer survival
than those with Charlson score ‘0’ in each diagnostic period. One-
year relative mortality among patients with Charlson score ‘1–2’
was higher than that of their Charlson score ‘0’ counterparts;
mortality ratio (MR)1995–1997¼2.43 (95% CI¼1.84–3.21),
MR1998–2000¼2.01, 95% CI¼1.53–2.63, and MR2001–2004¼1.76,
95% CI¼1.35–2.30. Five-year relative mortality was also higher
for patients with Charlson score ‘1–2’ compared to those with
Charlson score ‘0’; MR1995–1997¼1.89, 95% CI¼1.61–2.33, and
MR1998–2000¼1.60, 95% CI¼1.36–1.88. Among patients with
Charlson score ‘3þ’, 1-year relative mortality was 2–3 times
that of Charlson score ‘0’ patients in each time period;
MR1995–1997¼3.21, 95% CI¼1.69–6.08, MR1998–2000¼2.25, 95%
CI¼1.22–4.15, and MR2001–2004¼3.78, 95% CI¼2.51–5.68. A
similar effect of higher mortality among patients with a Charlson
score of ‘3þ’ was seen for 5-year mortality; MR1995–1997¼2.43 (95%
CI¼1.59–3.72) and MR1998–2000¼2.34 (95% CI¼1.65–3.33).
Although we observed little difference in the proportion of
patients alive 1-year post-diagnosis, overall, relative mortality was
lower for patients diagnosed between 2001 and 2004 after adjusting
for age and comorbidity with a 1-year MR¼0.80 (95% CI¼0.68–
0.95) for 2001–2004 compared to earlier periods and a 5-year
MR¼0.88 (95% CI¼0.80–0.97) for 1998–2000 (Table 3).
Stage information was available on 83% of the patients,
amounting to 7702 cases. On these patients, we carried out a
subanalysis (Table 4). For each Charlson score, there was a
decrease in local, distant, and unstaged disease and an increase in
regional stage over time. The prevalence of patients with unstaged
disease was higher among those with Charlson scores ‘1–2’ and
‘3þ’ compared to those with Charlson score ‘0’. After adjusting for
age and stage, 1-year relative mortality among patients with
Charlson score ‘1–2’ was approximately twice that of Charlson
score ‘0’ patients; MR1995–1997¼2.67, 95% CI¼1.92–3.72,
MR1998–2000¼2.14, 95% CI¼1.54–2.96, and MR2001–2004¼1.91,
95% CI¼1.36–2.69. Five-year relative mortality was also higher
for patients with a Charlson score ‘1–2’ compared to those with
a Charlson score ‘0’ in each period; MR1995–1997¼1.92, 95%
CI¼1.59–2.32 and MR1998–2000¼1.63, 95% CI¼1.35–1.98. Among
patients with a Charlson score ‘3þ’, 1-year relative mortality was
at least three times that of Charlson score ‘0’ patients; MR1995–
1997¼3.33, 95% CI¼1.62–6.87, MR1998–2000¼4.40, 95%
CI¼2.11–9.14, and MR2001–2004¼4.45, 95% CI¼2.58–7.66.
Patients with a Charlson score of ‘3þ’ had higher 5-year mortality;
MR1995–1997¼2.58, 95% CI¼1.56–4.25 and MR1998–2000¼3.78,
95% CI¼2.51–5.69.
DISCUSSION
There are two key findings of this population-based study. First,
we note a trend of poorer survival from 1995 through 2005
among breast cancer patients with comorbid diseases. To our
knowledge, this has not been reported previously. The second
key finding is that the overall prognosis for breast cancer patients
improved over time after adjusting for age and comorbidity,
similar to trends in other populations, where breast cancer
survival has improved over time (Sant et al, 2001; Althuis et al,
2005; Olsen et al, 2005).
Breast cancer survival can be improved via earlier and more
adequate diagnosis, and up-to-date guideline concordant treat-
ment. Over the period studied, adjuvant breast cancer treatment
adhered to the guidelines of the Danish Breast Cancer Cooperative
Group (www.dbcg.dk). There was no population-based mammo-
graphy screening in the study area. Moreover, there were no
major changes to diagnostic techniques in the study population,
although the sentinel lymph node biopsy (SLNB) was increasingly
used to spare women, with no sign of axillary disease, a full
dissection. Such increased use of SLNB may contribute to the
increase in regional stage over time for each Charlson category,
and may have caused some level of disease upstaging consistent
with trends in other countries (Schouten et al, 2002) (Cronin-
Fenton et al, 2007, manuscript in submission). The rising






















































































Figure 1 Kaplan–Meier survival curves for patients with breast cancer in
Denmark for three time periods for (A) Charlson score¼0, (B) Charlson
score¼1–2, and (C) Charlson score¼3þ.
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yBreast cancer survival has been extensively studied (Bergman
et al, 1991a,b; Ewertz, 1993; Carmichael et al, 2004; Althuis et al,
2005; Grant, 2005; Parkin et al, 2005); however, a relative paucity
of research has investigated the effect of comorbidity on breast
cancer and cancer survival generally (Bergman et al, 1991a; West
et al, 1996; Yancik et al, 2001). Our study extends the research
from several studies in western populations that indicate a
negative impact of comorbidity on cancer survival (Charlson
et al, 1987; West et al, 1996; Cronin et al, 2005). Our findings
compare to those of Charlson et al (1987) and West et al (1996),
highlighting the increased risk of mortality associated with mild
(Charlson score ‘1–2’) and severe comorbidity (Charlson score
‘3þ’) compared to little/no comorbidity (Charlson score ‘0’).
However, like the West study, we assessed all-cause mortality
rather than mortality from causes other than breast cancer as per
the Charlson paper. Thus cancer, or its treatment, may accelerate
the course of other pathological conditions, resulting in poorer
survival.
Studies have indicated that patients with comorbidities are often
(West et al, 1996; Potosky et al, 2002; Harlan et al, 2003a;
Louwman et al, 2005), but not always (Lash et al, 2003), less likely
to receive appropriate treatment. Lower survival of patients
with comorbidities may be attributable to physician or patient
preferences to forego the potential toxicities of cancer-directed
therapy, which could further compromise their health and quality
of life. Although less treatment of these patients may have a
negative impact on their survival – thus our observed poorer
survival among patients with comorbidities compared to those
with a Charlson score of zero – it is unlikely to influence their
survival over time as there has been little change to breast cancer
therapy from 1995 to 2004 (www.dbcg.dk).
An interesting finding of our study is the increase in median age
of patients with severe comorbidities. However, the prevalence of
Table 2 One-year and five-year survival after breast cancer for three comorbidity groups together with 1- and 5-year relative mortality for patients with
Charlson scores of 1–2 and 3+ compared to patients with a Charlson score of 0 for each diagnostic period
Charlson score
01 – 23 +
Breast cancer 1995–1997
Number of patients 2423 360 36
Median age (years) 59 73 72
1 year
% Survival 93% (91–94%) 79% (74–83%) 72% (55–84%)
Crude MR 1 (reference) 3.15 (2.41–4.13) 4.23 (2.24–8.00)
MR adjusted for age 1 (reference) 2.43 (1.84–3.21) 3.21 (1.69–6.08)
5 year
% Survival 71% (70–73%) 46% (41–51%) 39% (23–54%)
Crude MR 1 (reference) 2.38 (2.03–2.79) 3.09 (2.02–4.72)
MR adjusted for age 1 (reference) 1.89 (1.61–2.23) 2.43 (1.59–3.72)
Breast cancer 1998–2000
Number of patients 2518 431 54
Median age (years) 60 72 73
1 year
% Survival 93% (92–94%) 81% (77–85%) 80% (66–88%)
Crude MR 1 (reference) 2.74 (2.11–3.56) 3.07 (1.67–5.63)
MR adjusted for age 1 (reference) 2.01 (1.53–2.63) 2.25 (1.22–4.15)
5 year
% Survival 74% (72–75%) 54% (49–58%) 38% (24–51%)
Crude MR 1 (reference) 2.10 (1.79–2.47) 3.15 (2.22–4.48)
MR adjusted for age 1 (reference) 1.60 (1.36–1.88) 2.34 (1.65–3.33)
Breast cancer 2001–2004
a
Number of patients 2829 565 84
Median age (years) 59 72 76
1 year
% Survival 94% (93–95%) 85% (81–87%) 67% (55–76%)
Crude MR 1 (reference) 2.66 (2.06–3.44) 6.22 (4.17–9.27)
MR adjusted for age 1 (reference) 1.76 (1.35–2.30) 3.78 (2.51–5.68)
MR¼mortality ratio. Figures in parentheses show 95% confidence intervals.
aIt was not possible to compute a 5-year survival or mortality ratio for patients diagnosed between
2001 and 2004 because of the short follow-up period.
Table 3 One-year and five-year survival for breast cancer patients in
Denmark for three diagnostic periods
Diagnostic year
Breast cancer 1995–1997 1998–2000 2001–2004
Number of patients 2819 3003 3478
Median age (years) 61 62 62
1 year
% Survival 91% (89–92%) 91% (90–92%) 92% (91–93%)
Crude MR 1 (reference) 0.98 (0.83–1.16) 0.88 (0.75–1.04)
Age adjusted MR 1 (reference) 0.95 (0.80–1.12) 0.86 (0.73–1.02)
MR adjusted for age
and comorbidity
1 (reference) 0.92 (0.78–1.09) 0.80 (0.68–0.95)
5 year
% Survival 68% (66–69%) 70% (68–72%) —
Crude MR 1 (reference) 0.92 (0.84–1.01) —
Age adjusted MR 1 (reference) 0.90 (0.82–0.99) —
MR adjusted for age
and comorbidity
1 (reference) 0.88 (0.80–0.97) —
MR¼mortality ratio. Figures in parentheses indicate 95% confidence intervals.
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ypatients with a Charlson comorbidity score increased only slightly
over the period of diagnosis, largely driven by an increased
prevalence of patients with Charlson score ‘1–2’ rather than those
with score ‘3þ’. The trend of higher mortality among patients
with comorbidities remained even after adjusting for age and
stage. Breast cancer therapy (and cancer therapy in general) differs
according to patient age and menopausal status; older women can
be less likely than younger women to receive definitive care for
newly diagnosed breast cancer (Bergman et al, 1991a; Havlik et al,
1994; Hurria et al, 2003; Harlan et al, 2003b; Janssen-Heijnen et al,
2005; Louwman et al, 2005). In Denmark, chemotherapy is not
recommended as a standard treatment for hormone receptor-
negative patients over the age of 70 years. Furthermore, adjuvant
therapy is rarely given to patients over the age of 75 years at
diagnosis.
We note a higher prevalence of patients with unstaged disease
had Charlson scores of ‘1–2’ or ‘3þ’. This may suggest that the
presence of comorbidity at diagnosis either prevented a full
diagnostic work-up or the assignment of an appropriate stage.
Moreover, as anticancer therapy is directed by stage at diagnosis,
patients with unstaged disease may have received suboptimal
cancer treatment. These factors are likely to have exacerbated the
prognosis of these patients.
Our findings indicate an increase in the proportion of patients
with a comorbidity score between the first and last time periods.
This may be attributable to more complete recording of comorbid
disease in the hospital discharge registries, or indeed, a higher
likelihood that a patient with comorbidities could also be
examined for breast cancer.
Confounding by lifestyle factors (obesity, smoking, alcohol
consumption) both increase breast cancer risk (Thun et al, 1997;
Sonnenschein et al, 1999; McDonald et al, 2002), and contribute to
general health deterioration, likely to impact independently on
breast cancer prognosis (Sjol et al, 2003). Obesity, for example, is a
risk factor for post-menopausal breast cancer (approximately 75%
of cases) (Sonnenschein et al, 1999) and can exacerbate breast
cancer prognosis (Bastarrachea et al, 1994; Abrahamson et al,
2006; Carmichael, 2006). Comparable to trends in other western
countries (Boniface, 2006), obesity prevalence increased in
Denmark by 7.1% from 1987 to 2001, particularly after 1998 (Sjol
et al, 2003; Bendixen et al, 2004) and overweight prevalence in
women increased by 10% (Bendixen et al, 2004). Furthermore,
alcohol consumption (wine and hard liquor) and smoking have
increased in Denmark over the past 10–20 years (Statistics
Denmark, 2006). Consumption of alcohol before breast cancer
diagnosis is thought to intimate a poorer prognosis (Thun et al,
Table 4 One-year and five-year survival among breast cancer patients with available stage information (n¼7702) in Denmark for three diagnostic periods
Charlson score
01 – 23 +
Breast cancer 1995–1997 2225 281 29
Stage
Local 1077 (48%) 125 (44%) 14 (48%)
Regional 962 (39%) 88 (31%) 6 (21%)
Distant 154 (7%) 23 (8%) 4 (14%)
Unstaged 132 (6%) 45 (16%) 5 (17%)
1-year
% Survival 94% (93–95%) 81% (76–86%) 72% (52–85%)
Crude MR 1 (reference) 3.45 (2.50–4.75) 5.45 (2.67–11.14)
MR adjusted for age and stage 1 (reference) 2.67 (1.94–3.72) 3.33 (1.62–6.87)
5-year
% Survival 73% (71–75%) 48% (42–53%) 45% (27–62%)
Crude MR 1 (reference) 2.44 (2.04–2.93) 2.92 (1.78–4.79)
MR adjusted for age and stage 1 (reference) 1.92 (1.59–2.32) 2.58 (1.56–4.25)
Breast cancer 1998–2000 2399 301 42
Stage
Local 1149 (48%) 130 (43%) 25 (60%)
Regional 998 (42%) 105 (34%) 9 (21%)
Distant 138 (6%) 27 (9%) 1 (2%)
Unstaged 114 (5%) 43 (14%) 7 (17%)
1-year
% Survival 94% (93–95%) 83% (78–86%) 81% (66–90%)
Crude MR 1 (reference) 3.22 (2.35–4.42) 3.61 (1.77–7.36)
MR adjusted for age and stage 1 (reference) 2.14 (1.54–2.96) 4.40 (2.11–9.14)
5-year
% Survival 75% (74–77%) 54% (48–60%) 40% (25–54%)
Crude MR 1 (reference) 2.27 (1.88–2.73) 3.44 (2.30–5.13)
MR adjusted for age and stage 1 (reference) 1.63 (1.35–1.98) 3.78 (2.51–5.69)
Breast cancer 2001–2004 2566 357 52
Stage
Local 1133 (44%) 148 (41%) 19 (37%)
Regional 1170 (46%) 133 (37%) 24 (46%)
Distant 114 (4%) 23 (6%) 3 (6%)
Unstaged 149 (6%) 53 (15%) 6 (12%)
1-year
% Survival 95% (94–96%) 87% (83–90%) 71% (57–81%)
Crude MR 1 (reference) 2.80 (2.01–3.89) 6.43 (3.77–10.97)
MR adjusted for age and stage 1 (reference) 1.91 (1.36–2.69) 4.45 (2.58–7.66)
MR¼mortality ratio. Figures in parentheses indicate 95% confidence intervals.
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y1997; McDonald et al,2 0 0 2 ) ,b u tf i n d i n g sa r ei n c o n s i s t e n t( E w e r t z ,
1993). The timing of the increased prevalence of obesity, alcohol
consumption, and smoking corresponds with, and may, therefore,
have impacted on survival among patients with severe comorbidities.
The main strengths of our study are its large size, the uniformly
organised health-care system facilitating a population-based
design with accurate survival estimates, reduced selection bias,
and complete follow-up. Our study has some limitations: it may be
prone to incidence-prevalence bias. Prevalent comorbid disease
includes cases with long-term survival, who therefore have better
survival than incident cases, in whom the full severity of
comorbidity is represented (Goldman et al, 1983). To minimise
such bias, we included comorbidity history recorded up to 10 years
before breast cancer diagnosis. We used the Charlson comorbidity
index to measure comorbidity, which has been used to assess the
impact of comorbidities in many disease settings (Greenfield et al,
1993; Newschaffer et al, 1997; Horton et al, 2001; Mandelblatt et al,
2001). The Charlson index has some limitations, however: (a) it
does not incorporate a measure of function (Greenfield et al, 1987);
patients with identical scores can vary in comorbid disease
severity, for example, manageable diabetes is classified within
the same category as severely debilitating chronic obstructive
pulmonary disease (Charlson score ‘1’). (b) The Charlson index is
based on discharge diagnoses, which may not be entirely accurate.
(c) The registration of comorbidities may have changed over the
years, likely towards more complete registration.
In conclusion, we found a negative impact of comorbidity on
breast cancer mortality. As breast cancer is the most commonly
diagnosed cancer among women and the fifth most common cause
of cancer-related death in women (Parkin et al, 2005), our
observed increase in mortality among patients with severe
comorbidity is of clinical and public health concern.
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